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Available online 9 July 2016DNA topoisomerases (Topo) aremultifunctional enzymes resolving DNA topological problems such as those aris-
ing during DNA replication, transcription and mitosis. Mammalian cells express 2 class II isoforms,
Topoisomerases IIα (Topo IIα) and IIβ (Topo IIβ), which have similar enzymatic properties but are differently
expressed, in dividing and pluripotent cells, and in post-mitotic and differentiated cells respectively. Pre-adipo-
cytes re-enter the cell cycle prior to committing to their differentiation and we hypothesised that Topo II could
contribute to these processes. We show that Topo IIα expression in 3T3-L1 cells is induced within 16 h after
the initiation of the differentiation programme, peaks at 24 h and rapidly declines thereafter. In contrast Topo
IIβ was present both in pre-adipocytes and throughout differentiation. Inhibition of PI3K with LY294002,
known to prevent adipocyte differentiation, consistently reduced the expression of Topo IIα, whereas a clear ef-
fect on Topo IIβwas not apparent. In addition, inhibition ofmTORwith rapamycin also reduced the protein levels
of Topo IIα. Using speciﬁc class IA PI3K catalytic subunit inhibitors, we show that p110α inhibition with A66 has
the greatest reduction of Topo IIα expression and of differentiation, as measured by triglyceride storage. The
timing of Topo IIα expression coincides with themitotic clonal expansion (MCE) phase of differentiation and in-
hibition of Topo II with ICRF-187 during this stage decreased PPARγ1 and 2 protein levels and triglyceride stor-
age, whereas inhibition later on has little impact. Moreover, the addition of ICRF-187 had no effect on the
incorporation of EdU during S-phase at day 1 but lowered the relative cell numbers on day 2. ICRF-187 also in-
duced an increase in the centri/pericentromeric heterochromatin localisation of Topo IIα, indicating a role for
Topo IIα at these locations during MCE. In summary, we present evidence that Topo IIα plays an important
role in adipogenesis during MCE and in a PI3K/mTOR-dependent manner. Considering that Topoisomerases II
are targets in cancer chemotherapy, our results highlight that treatment of cancer with Topo II inhibitors may
alter metabolic processes in the adipose tissue.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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PPARγ1. Introduction
Obesity, a disorder characterised by an increase in white adipose tis-
sue mass, is a major risk for the development of type II diabetes, cardio-
vascular diseases, and some cancers [1]. Increased white adipose tissue
mass is believed to be due to, not only adipocyte hypertrophy, but also
hyperplasia [2]. Although extensively studied, the molecular mecha-
nisms regulating these processes are however not fully understood
and warrant further research efforts.AAT/enhancer-binding protein;
; IR, insulin receptor; PI3K,
and β, DNA Topoisomerase IIα
butyl-2-methylxanthine; PARP,
, pericentromeric chromatin.
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. This is an open access article underThe 3T3-L1 pre-adipocyte cell line has providedmuch of our knowl-
edge in the adipocyte differentiation processes [3]. Following cell cycle
arrest, these cells respond to the combined treatment of differentiation
inducers, consisting of 3-isobutyl-1-methylxanthine (IBMX), dexa-
methasone and insulin, re-enter the cell cycle for about 2 rounds of mi-
tosis, before the induction of terminal differentiation [4]. Cell cycle re-
entry, a process also called mitotic clonal expansion (MCE), followed
by cell cycle arrest, is thought to be required for terminal differentiation
of adipocytes [4,5]. DNA replication is thought to permit the re-organi-
sation of the chromatin landscape necessary for the initiation of
adipogenic gene expression orchestrated by the nuclear receptors
CCAAT/enhancer-binding protein (C/EBP) β and peroxisome
proliferator-activated receptor γ (PPARγ) [6,7]. This implies a link be-
tween cell cycle regulation and metabolic processes [8]. Indeed the fol-
lowing cell cycle regulators, such as the transcription factor E2Fs and the
G1 factors p21, p27, cyclin D3 and cyclin dependent kinase 4 have been
shown to regulate MCE and to contribute to adipogenesis by inducingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[9–11]. Consistently, inhibition of DNA synthesis blocks both MCE and
adipogenesis [4] by preventing the production of a PPARγ ligand prior
to the optimal transcriptional activation of PPARγ [12]. Although nu-
merous studies have clearly shown that MCE is required for adipogene-
sis, the underlying molecular mechanisms triggering MCE are however
not fully understood.
Adipocytes respond to insulin by activating the insulin receptor (IR),
the phosphorylation of IR substrates and the activation of the class I
phosphoinositide 3-kinase (PI3K) signalling pathway, which ultimately
leads to the transcription of speciﬁc insulin responsive gene products
and regulation of glucose and lipid homeostasis [13–15]. Activation of
class I PI3K generates the polyphosphoinositide lipid product phos-
phatidylinositol(3,4,5) triphosphate (PtdIns(3,4,5)P3), which is respon-
sible for the activation of protein kinase B (PKB)/Akt in 3T3-L1 cells [16].
PKB/Akt is activated by sequential phosphorylation on Thr308 and
Ser473 by 3-phosphoinositide-dependent protein kinase-1 (PDK1)
and mammalian target of rapamycin (mTOR) complex 2 respectively
[17,18]. Activated Akt can translocate to different intracellular sites
where it phosphorylates a myriad of substrates. When in the nucleus,
PKB/Akt phosphorylates and inactivates the transcription factor FoxO1
by nuclear exclusion, thus permitting adipogenic gene transcription
[19]. The PI3K-PKB/Akt pathway is known to be essential for adipogen-
esis [20–24] and PI3K inhibition was shown to prevent MCE in 3T3-L1
cells [21,25], but the underlyingmolecularmechanisms linking the acti-
vation of the PI3K pathway and the induction of MCE are unclear.
DNA topoisomerases are a family of enzymes that resolve DNA topo-
logical features such as catenation and supercoiling, arising during DNA
replication, transcription and sister chromatid entanglement duringmi-
tosis [26,27]. DNA topoisomerases consist of two classes, type I and type
II which catalyse single and double strand breaks respectively. Mamma-
lian cells express two type II isoforms (Topo IIα and β) that are encoded
by different genes. They both have the same catalytic activity but have
different expression patterns during cell division and distinct cellular
functions [26,28]. Topo IIα is expressed in dividing and pluripotent
cells while Topo IIβ is found in post-mitotic and differentiating cells.
Topo IIα is highly expressed in actively dividing cells whereas Topo
IIβ is more abundant in terminally differentiated cells [29–32]. The
level of Topo IIα expression varies during cell-cycle progression with
lowest levels observed in G1 followed by a steady increase peaking at
the G2 andMphases of the cell cycle [33–35]. Topo IIβ expression levels
vary less than Topo IIα throughout the cell cycle and either remain con-
stant or decrease [33,35]. In light of this,we hypothesised that Topo II, in
particular Topo IIα, may participate in MCE and adipocyte differentia-
tion. We have now shown that Topo IIα levels are up-regulated in the
early steps of adipocyte differentiation in a PI3K/mTOR-dependent
manner. The precise increase of Topo IIα coincides with the time
frame of occurrence of MCE and that its activity contributes to MCE
and is thus required for adipocyte differentiation.
2. Materials and methods
2.1. Reagents
Calf serum, dexamethasone, dexrazoxane (ICRF-187), Dulbecco's
Modiﬁed EaglesMedium (DMEM), dimethylsulfoxide (DMSO), fetal bo-
vine serum (FBS), IBMX, insulin, LY294002, Oil Red O, Mammalian Pro-
tease Inhibitor Cocktail, penicillin/streptomycin and rapamycin were
from Sigma-Aldrich. Benzonase was fromMerckMillipore. The PI3K se-
lective inhibitors targeting p110α (A66) and p110β (TGX-221) were
from Selleck Chemicals and p110δ (PI3065) from Cayman Chemical re-
spectively. The following antibodies were used: anti-PI3K p110α
(4249), anti-Poly(ADP-ribose) Polymerase (PARP) (9542), anti-ribo-
somal protein S6 (2217) and anti-phospho-S240/S244 ribosomal
protein S6 (5364) from Cell Signaling Technology; anti-DNA Topoisom-
erase IIα (ab52934) from Abcam; anti-PPARγ (MA5-14889) fromThermoFisher; anti-DNA Topoisomerase IIβ (HPA024120) from
Sigma-Aldrich and anti-β-Actin (sc-69879), anti-PI3K p110β (IgM, sc-
376492), anti-PI3K p110δ (sc-7176), anti-cyclin A (sc-596) from Santa
Cruz Biotechnology. Hoechst, goat anti-mouse/rabbit conjugated with
horseradish peroxidase (HRP) and Alexa 488-conjugated secondary an-
tibodies were from Life Technologies. HRP-conjugated goat anti-mouse
IgMwas from Abcam. TO-PRO-3 nucleic acid stain (T3605) and Prolong
Gold antifade reagent (p36930) for mountingwere from Thermo Fisher
scientiﬁc.
2.2. Cell culture and differentiation of 3T3-L1 cells
3T3-L1 ﬁbroblasts were kindly provided by Lise Madsen (University
of Copenhagen, Denmark) cultured in high-glucose DMEM supple-
mented with 10% calf serum and 100 units/ml penicillin and 100 μg/
ml streptomycin and maintained at about 70% conﬂuence. To induce
differentiation, cells were grown to conﬂuence. At two-three days post
conﬂuency (day 0), 3T3-L1 cells were incubated with a differentiation
cocktail (abbreviated MDI) containing 500 μM IBMX, 250 nM dexa-
methasone and 5 μg/ml insulin in DMEM with 10% FBS and antibiotics
for 2 days. After 2 days (day 2), the differentiation medium was re-
moved and the cells were incubated in DMEM-10% FBS and antibiotics
containing 5 μg/ml insulin (insulin medium) for 2 more days. At day 4
and 6 the mediumwas changed to DMEM-10% FBS and antibiotics. Ad-
ipocyte differentiation was veriﬁed for each thawed batch of cells by Oil
Red O staining at day 0 and day 7. For PI3K and rapamycin inhibitor ex-
periments, 3T3-L1 cells were pre-incubated on day 0 for 1 h with inhib-
itors or DMSO before the addition of the MDI medium containing
inhibitors or DMSO aswell as before the addition of the insulinmedium
on day 2. Inhibitors were not added onwards from day 4. Cells were
then either lysed on day 1 or stained with Oil Red O on day 7. For Topo-
isomerase II inhibitor treatments, 50 μg/ml of ICRF-187 or equal volume
of DMSO was added to the MDI medium on day 0 and with the insulin
mediumon day 2 and not thereafter. Cells were either lysed forWestern
immunoblotting on day 3 or stained with Oil Red O on day 7. For treat-
ments from days 0–2 or 3–5, 50 μg/ml of ICRF-187 or equal volume of
DMSO was added either with the MDI medium on day 0 or directly
into existing insulin medium on day 3. Insulin medium was then
changed to DMEM-10% FBS and antibiotics on day 5 rather than day 4
and no ICRF-187 was added from this point onwards. This gave a total
of 2 days of exposure to the inhibitor or DMSO (days 0–2 or 3–5).
Cells were then either lysed for Western immunoblotting on day 5 or
stained with Oil Red O on day 7.
2.3. Oil Red O staining
On day 0 or 7 the cells were washed twice with PBS and ﬁxed with
3.7% paraformaldehyde (PFA) for 15 min at room temperature. Cells
were stained with 0.3% Oil Red O in 60% isopropanol working solution
for 1 h at room temperature and washed 5 times with MilliQ H2O. The
plateswere left to dry at room temperature and stored at 4 °C. For quan-
tiﬁcation, Oil Red Owas dissolved with isopropanol and the absorbance
was measured at 500 nm.
2.4. SDS-PAGE and Western immunoblotting
Cells were washed with cold PBS and lysed in RIPA lysis buffer
(50 mM Tris pH 8.0, 0.5% deoxycholic acid, 150 mM NaCl, 1% NP-40,
0.1% SDS) supplemented with 5 mM NaF, 2 mM Na3VO4 and 1× Prote-
ase Inhibitor Cocktail and sonicated in an ultrasonic bath for 1–2 min or
incubated with 16 U benzonase (for 35 mm plates) for 30 min on ice.
Excess lipidswere removed (day 5 and 7 usually). Protein concentration
was determined using BCA reagents (Pierce) and equal amount of pro-
teins (40–50 μg) were resolved by SDS-PAGE and transferred to nitro-
cellulose membranes. Membranes were blocked in 7% fat-free milk in
TBS-T (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at
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bodies and subsequently with secondary antibodies conjugated to
HRP for 1 h at room temperature. Protein detection was performed by
enhanced chemiluminescence (ECL) using the SuperSignal West Pico
or Femto Chemiluminescent Substrate (Pierce) and detected with a
BioRad ChemiDoc™ Xrs+. The membranes were stripped for 20 min
at RT in Restore™ Western Blot Stripping Buffer (Pierce), washed
in TBS-T, blocked again and probed with the corresponding secondary
antibody to detect any remaining signal prior to further immunoblot-
ting when required. Equal protein loading was conﬁrmed by
immunodetection of β-actin. Protein bands were quantiﬁed using
ImageJ and normalised to β-actin and then to control.
2.5. Immunoﬂuorescence staining
3T3-L1 cells, seeded on 12 mm coverslips, were incubated with the
MDI medium at day 0. Cells were ﬁxed with 3.7% paraformaldehyde
for 10min at room temperature, washed twicewith PBS, permeabilised
with 0.25% Triton X-100 in PBS for 10 min and blocked for 1 h with
blocking buffer (3% fatty-acid free BSA in PBS-T). The cellswere incubat-
ed overnight at room temperature with anti-Topo IIα or anti-Topo IIβ
antibodies diluted at 1:100 in blocking buffer, followed by incubation
with anti-rabbit IgG antibody conjugated to Alexa-488 diluted in
blocking buffer (1:200) for 1 h at room temperature. Washes were per-
formed with 0.05% PBS­T after antibody incubations. The coverslips
were stained for 20 min at room temperature with TO-PRO-3 nucleic
acid stain before mounting. Control staining with secondary antibody
alone under the same staining and exposure conditions showed no
staining. Imageswere acquiredwith a Leica TCS SP5 confocal laser scan-
ningmicroscope equipped with a 63×/1.4 oil immersion lens and using
488 nm and 633 nm laser lines. Images were processed with the Leica
application suite version 4.4.
2.6. EdU staining
EdU staining was performed according to the Invitrogen's Click-iT
EdU imaging kit (C10339). 3T3-L1 cells were seeded on 12 mm cover-
slips. 2–3 days after reaching conﬂuency, cells were incubated with
MDI medium containing either 50 μg/ml ICRF-187 or DMSO for 1 or
2 days. Cells were incubated with 10 μM EdU for the last 2 h prior ﬁxa-
tion. Cells were ﬁxed for 15 min at room temperature in 3.7% PFA on
days 0, 1 and 2. EdU was stained for 30 min with Alex-594 according
to the kit protocols (except buffer reaction additive was prepared as
10 × 500 mM ascorbic acid in H20). Cells were then blocked for 1 h at
room temperature in 3%BSA, 0.1% Triton X-100 in PBS before incubation
with anti-Topo IIα (1:100) and subsequently with anti-mouse IgG sec-
ondary antibody conjugated to Alexa-488 (1:200) in blocking buffer for
1 h at room temperature. Washes were performed with 0.05% PBS-T
after each antibody incubation. DNA staining was then done using
Hoechst for 30 min at room temperature before mounting. Images
were acquired with a Leica DMI6000B ﬂuorescence microscope using
a 40× objective.
3. Results
3.1. DNA Topoisomerase IIα is transiently expressed during 3T3-L1
preadipocyte differentiation in a PI3K-dependent manner
To investigate whether Topo IIα and/or β play a role in the mitotic
clonal expansion occurring during the early stages of adipocyte differ-
entiation, we ﬁrst evaluated the expression levels of each isoform
upon stimulation of 3T3-L1 cells with the differentiation cocktail for
the ﬁrst 3 days and up to 7 days (Fig. 1A). The expression levels of
both isoforms were distinct throughout the time course. Topo IIα was
undetectable in post-conﬂuent cells (day 0), but its expression in-
creased within 16 h of stimulation and peaked at day 1, whichcorrelated with an increase in expression of cyclin A. The expression
levels of Topo IIα then declined fromday 2. The decrease in Topo IIα co-
incidedwith an increase in PPARγ2 expression. In contrast, Topo IIβwas
present in post-conﬂuent cells as well as throughout adipogenesis. The
levels of Topo IIβ varied between experiments showing either an in-
crease from day 0 to day 1 (Fig. 1A) or constant levels throughout the
time course (Fig. 1E and Supplementary Fig. S1). The pattern of protein
expression of both isoforms is consistent with the reported transcript
levels by Mikkelsen et al. [36] (Supplementary Fig. S2) and for Topo
IIα by Soukas et al. [37]. In immunostaining analyses, we showed that,
similarly to Western analyses, a great increase in cells stained for Topo
IIα at day 1 compared to day 0, whereas the majority of cells in both
day 0 and day 1 stained for Topo IIβ (Fig. 1B). In addition, Topo IIα ex-
hibited two different patterns of localisation, either diffuse throughout
the nucleus or in foci strongly stained by the DNA dye TO-PRO-3 and
known as centric/pericentric heterochromatin (PCH) [38]. The
localisation pattern of Topo IIβ was mostly diffuse with occasional
cells with a punctate pattern but it did not change overall between
day 0 and 1 (Fig. 1B). Since the differentiation of 3T3-L1 cells has been
shown be dependent on the PI3K pathway [21,23,25,39], we investigat-
ed the effect of the pan-PI3K inhibitor, LY294002, on the protein levels
of Topo IIα and β upon differentiation at day 1. Consistent with other
studies, inhibition of PI3K with LY294002 greatly reduced the storage
of triglycerides (Fig. 1C–D). Interestingly, the protein levels of Topo IIα
detected at day 1 were also consistently reduced by the addition of
LY294002 (Fig. 1E–F). However, the effects of PI3K inhibition on Topo
IIβ expression were a lot more variable with the addition of LY294002
(Fig. 1E–F), depending on the level detected in day 1. We monitored
the activity of the PI3K pathway by analysing the levels of phospho-
S240/S244 of the 40S ribosomal protein S6 (pRS6). As expected, the
levels of pRS6 were elevated at day 1 and were then decreased follow-
ing PI3K inhibitionwhile total RS6 levels remained unchanged (Fig. 1E).
3.2. All class IA PI3K catalytic isoforms are expressed in 3T3-L1 cells during
differentiation but selective inhibition of p110α reduces differentiation and
DNA Topoisomerase IIα
The PI3K class IA family of enzymes consists of the catalytic subunits
p110α, p110β and p110δ and the expression pattern of each isoform
was investigated upon adipocyte differentiation. p110α, β and δ were
all expressed and their levels remained relatively stable throughout
the time course (Fig. 2A). We therefore sought to determine which
PI3K isoforms contribute to adipogenesis as well as the regulation of
the levels of Topo IIα using the selective inhibitors A66 (p110α), TGX-
221 (p110β) and PI3065 (p110δ). Addition of A66 reduced the storage
of triglycerides dose-dependently reaching the same levels obtained
by LY294002 addition at the highest concentration of A66 (10 μM)
(Fig. 2B–C). PI3065 had little effect at 0.1 or 1 μM but greatly decreased
triglyceride storage at the highest concentration of 10 μM. In contrast
TGX-221 had the least effect of all 3 inhibitors. The levels of Topo IIα
were also affected by the addition of these PI3K inhibitors with most ef-
fect seen at higher doses of A66 (1 and 10 μM), TGX (10 μM) and PI3065
(10 μM) reﬂecting the results obtained for the effects of inhibitors on
storage of triglycerides (Fig. 2D–E).
3.3. mTOR regulates the protein levels of DNA Topoisomerase IIα
mTOR, which is known to control protein synthesis, is also reported
to contribute to adipogenesis [39,40] andwe therefore evaluated the ef-
fect of rapamycin, an inhibitor of mTOR, on triglyceride storage and
Topo IIα protein expression (Fig. 3). Rapamycin dramatically lowered
the deposition of triglycerides at concentrations as low as 1 nM (Fig.
3A–B). Accordingly, the expression levels of Topo IIα also decreased
with the addition of rapamycin (Fig. 3C–D), showing therefore a role
for the PI3K/mTOR pathway in regulation Topo IIα protein synthesis.
Fig. 1. Expression proﬁle of Topo IIα and β during adipocyte differentiation of 3T3-L1 cells and effect of pan-PI3K inhibition on their expression. A. RepresentativeWestern blots of 3T3-L1
cells whole cell extracts, obtained at day 0 (D0) and up to 7 days of differentiation (D7), probed with anti-Topo IIα, anti-Topo IIβ, anti-cyclin A, anti-PPARγ and anti-β-actin as a loading
control. B. Immunostaining of 3T3-L1 cells ﬁxed at day 0 and day 1 with anti-Topo IIα and β and nuclear counterstained with TOPRO. Lower panels show magniﬁed examples, scale bar
indicates 10 μm (63×). C. Representative photos of 3T3-L1 cells ﬁxed and stained with Oil Red O on day 0 (D0) or day 7 (D7) of differentiation in the presence of 10 μM LY294002 (+) or
DMSO (−) for the ﬁrst 4 days (photos of plates on top, microscope 10×magniﬁcation on bottom), D. Quantiﬁcation of Oil Red O staining from day 7 (D7) relative to DMSO control (−). E.
RepresentativeWestern blots of 3T3-L1 whole cell extracts obtained at day 0 (D0) or day 1 (D1) of differentiation after incubation with 10 μM LY294002 (+) or DMSO (−), probedwith
anti-Topo IIα, anti-Topo IIβ, anti-ribosomal protein S6 (RS6), anti-phospho-S240/S244-ribosomal protein S6 (pRS6) and β-actin as loading control, F. Quantiﬁcation of Topo IIα and Topo
IIβ protein banddensitometry (top band only (*)) fromday 1 (D1) normalised toβ-actin and then to DMSOcontrol (−). All quantiﬁcations are from5 independent experiments, shown as
mean ± SDs. Bands of interest on Western blots are highlighted with * if multiple.
1596 R.G. Jacobsen et al. / Cellular Signalling 28 (2016) 1593–16033.4. DNA Topoisomerase II activity is required for adipocyte differentiation
and PPARγ1/2 up-regulation
Topoisomerase II inhibition with merbarone has previously been
shown to reduce the transcription of PPARy2 and several PPARy2-de-
pendent genes in 3T3-L1 cells at later stages of differentiation via the in-
hibition of PARP1 (ARTD1) [41,42]. To further evaluate Topoisomerase II
activity requirement in adipocyte differentiation, post-conﬂuent 3T3-L1
cells were incubated with the Topoisomerase II inhibitor, ICRF-187. In-
hibition of topoisomerase II resulted in a decrease in both stored triglyc-
erides (Fig. 4A–B) and PPARγ1 and 2 protein levels (Fig. 4C–D).Considering that the levels of Topo IIα decrease from day 2 of stimula-
tion but Topo IIβ remains present throughout the time course (Fig.
1A), 3T3-L1 cells were differentiated in the presence of ICRF-187 either
for the ﬁrst 2 days or days 3–5 to elucidate the requirement of Topo II in
early or late differentiation phases. Addition of ICRF-187 at the start of
differentiation for days 0–2 resulted in a greater decrease in the amount
of stored triglycerides than when added later at days 3–5 (Fig. 4E–F).
This was reﬂected with a greater decrease in the levels of PPARγ1 and
2when cells were treated early at days 0 and 2, compared to later treat-
ments at days 3–5 (Fig. 4G–H) when the levels of Topo IIα have greatly
declined (Fig. 1A). To verify that the effect of topoisomerase inhibition
Fig. 2. Expression levels of class IA PI3K catalytic isoforms during differentiation and effect of their selective inhibition on differentiation and Topo IIα expression. A. Representative
Western blots of whole cell extracts from 3T3-L1 cells, day 0 (D0) and up to 7 days (D7) of differentiation, blots probed with anti-PI3K p110α, β, δ and anti-β-actin as a loading
control. B. Representative photos of 3T3-L1 cells ﬁxed and stained with Oil Red O on day 0 (D0) or day 7 (D7) of differentiation after incubation for the ﬁrst 4 days with the selective
PI3K inhibitors for p110α (A66), p110β (TGX-221) or p110δ (PI3065), LY294002 or DMSO (photos of plates on top, microscope 10× magniﬁcation on bottom), C. Quantiﬁcation of Oil
Red O staining from day 7 (D7) plates normalised to DMSO. D. Representative Western blots of 3T3-L1 whole cell extracts obtained at day 0 (D0) or day 1 (D1) of differentiation in the
presence of PI3K inhibitors or DMSO, probed with anti-Topo IIα, anti-ribosomal protein S6 (RS6), anti-phosphoS240/S244-ribosomal protein S6 (pRS6) and β-actin as loading control,
E. Quantiﬁcation of Topo IIα protein band densitometry from day 1 (D1) normalised to β-actin and then to DMSO. All quantiﬁcations were from a minimum of 2–3 independent
experiments, shown as means ± SDs. Bands of interest on Western blots are highlighted with * if multiple.
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under the same conditions. The PARP levels were increased at day 3
(Fig. 4C) and day 5 (Fig. 4G) butwe could not detect any PARP cleavage.
3.5. DNA Topoisomerase IIα activity contributes to cell proliferation, but not
DNA synthesis, during MCE
Since Topo II inhibition has a greatest effect on adipocyte differenti-
ationwhen used during the ﬁrst 2 days (Fig. 4E–H) and since Topo IIα is
transiently expressed in the early stages of differentiation (Fig. 1A), we
wondered if Topo IIα played a role in the MCE phase. We ﬁrst assessed
the effect of ICRF-187 on DNA synthesis using EdU staining. A large in-
crease in the number of Topo IIα-positive cells was seen at day 1 com-
pared to day 0 (from 2.0 ± 1.4 to 47.8 ± 5.4%), and on average abouthalf of these cells at day 1 were also labelled with EdU (Fig. 5A–B). In
all conditions, most cells labelled with EdU were also Topo IIα-positive
and on average less than 1% of cells were both EdU-positive and Topo
IIα-negative. At day 2, the number of Topo IIα-positive cells decreased
slightly and only a small proportion of these cells were also EdU-posi-
tive (4.0 ± 2.1%), compared to day 1. Addition of ICRF-187 to 3T3-L1
cells did not signiﬁcantly affect the number of EdU-positive cells at
day 1 but a slight decrease was apparent at day 2 of differentiation
(Fig. 5A–B). Moreover, the number of Topo IIα-positive cells remained
elevated in ICRF-187-treated cells at day 2, perhaps owing to the
mode of action of the inhibitor clamping Topo IIα to DNA and thus
maybe preventing its release from DNA and its degradation [43–45]
(Fig. 5A–B).We have shown that Topo IIα has two different distribution
patterns in the nucleus at day 1, i.e. either diffuse or concentrated in
Fig. 3.mTOR controls the protein levels of Topo IIα. A. Representative photos of 3T3-L1 cell plates ﬁxed and stainedwith Oil Red O stain on day 0 (D0) or day 7 (D7) of differentiation after
incubation for the ﬁrst 4 days with rapamycin or equivalent volume DMSO (photos of plates on top, microscope 10× magniﬁcation on bottom), B. Oil Red O from day 7 (D7) plates was
then extracted and quantiﬁed, relative absorbance normalised to DMSO control. C. Representative Western blot of 3T3-L1 whole cell extracts on day 0 (D0) or on day 1 (D1) of
differentiation after incubation with rapamycin or equivalent volume DMSO, probed with anti-Topo IIα, anti-ribosomal protein S6 (RPS6), anti-phosphoS240/S244-ribosomal protein
S6 (pRS6) and β-actin as loading control, D. Quantiﬁcation of Topo IIα protein band densitometry from day 1 (D1) normalised to β-actin and then to DMSO. All quantiﬁcations are
from 3 independent experiments, shown graphs as mean ± SD.
1598 R.G. Jacobsen et al. / Cellular Signalling 28 (2016) 1593–1603DNA-stain rich foci known as PCH (Fig. 1B). The PCH/diffuse staining
ratio was of 0.76 on day 1 and of 0.89 on day 2 (Fig. 5C). ICRF-187 treat-
ment caused the ratio to increase on both day 1 and 2 compared to un-
treated cells to 6.6 and 3.1 respectively (Fig. 5C). The increase in the
proportion of cells stained with Topo IIα in PCH may again most likely
be due to the mode of action of the inhibitor and may suggest that
Topo IIα is particularly active at PCH at the very early stages of adipocyte
differentiation (Fig. 5C). In addition Topo IIα co-stains oftenwith EdU at
these sites (Fig. 5A), which may indicate that Topo IIα participates in
DNA synthesis of PCH. In sum, Topo II inhibition had no effect or very lit-
tle on DNA synthesis on both day 1 and 2 of differentiation. We there-
fore analysed the relative cell numbers under the same conditions and
showed a decrease in the relative cell number in ICRF-187-treated
cells on day 2 compared to DMSO-treated cells (Fig. 5D).
4. Discussion
Cell division, also speciﬁcally known as MCE, is thought to be a pre-
requisite for adipocyte differentiation [4,5]. Entry into S phase and DNA
synthesis have been shown to be particularly important [46]. In this re-
port, we provide evidence that Topo II activity is required for pre-adipo-
cyte differentiation, acting notably at the early steps duringMCE. This issupported by the following results. Firstly, when Topo II is inhibited
prior to the onset of MCE, i.e. from days 0 to 2, the effect on differentia-
tionwas greatest compared to later inhibition at days 3–5. Secondly, the
levels of Topo IIα are transiently induced during differentiation and
peak at day 1 when DNA synthesis and cyclin A, an S phase indicator,
are highest. Finally, cells that are in S phase at day 1 almost all stain
for Topo IIα. More speciﬁcally, Topo IIα localises to sites of DNA replica-
tion at day 1. In contrast, the expression and localisation of Topo IIβ does
not tend to correlate with S phase. Our ﬁndings would hence point to a
role for Topo IIα at this stage of differentiation. The contribution of Topo
IIβ to MCE cannot be excluded however as it is expressed throughout
differentiation and thus its expression overlaps with that of Topo IIα.
Moreover, ICRF-187, which was used in this study, is thought to target
both Topo IIα and Topo IIβ [43], although another study showed that
the activity of Topo IIα may be more affected than Topo IIβ by ICRF-
187 in HeLa cells due to increased retention to DNA [47].
In this study, we have observed that Topo IIα localises to intense
DNA-stained areas at day 1, also known as chromocenters, consisting
of centromeric and pericentromeric heterochromatin, which are partic-
ularly prominent inmurine cells [38,48]. Similarly, the transcription fac-
tor CCAAT/enhancer-binding proteins β and δ (C/EBPβ and δ) were
reported to show the same pattern by interacting with satellite DNA
Fig. 4. Topo II activity is required for adipocyte differentiation and PPARγ1 and 2 up-regulation. A. Representative photos of 3T3-L1 cells ﬁxed and stainedwith Oil RedO on day 0 (D0) and
day 7 (D7) of differentiation after incubation with 50 μg/ml of Topoisomerase II inhibitor ICRF-187 (+) or equivalent volume of DMSO (−) for the ﬁrst 4 days (photos of plates on top,
microscope 10× magniﬁcation on bottom), B. Quantiﬁcation of Oil Red O staining from day 7 (D7) normalised to DMSO (−). C. Representative Western blots of 3T3-L1 whole cell
extracts on day 0 (D0) or on day 3 (D3) of differentiation after incubation with 50 μg/ml of ICRF-187 (+) or DMSO (−) for the ﬁrst 3 days of differentiation, probed with anti-PPARγ,
anti-PARP and β-actin as a loading control, D. Quantiﬁcation of PPARγ1 and 2 protein bands from day 3 (D3) normalised to β-actin and then to DMSO (−). E. Representative photos of
3T3-L1 cells ﬁxed and stained with Oil Red O on day 0 (D0) and day 7 (D7) of differentiation after incubation 50 μg/ml of ICRF-187 (+) or DMSO (−) for days 0–2 or 3–5 (photos of
plates on top, microscope 10× magniﬁcation on bottom), F. Quantiﬁcation of Oil Red O staining from day 7 (D7) normalised to DMSO control (−). G. Representative Western blots of
3T3-L1 whole cell extracts obtained on day 0 (D0) or on day 5 (D5) of differentiation after incubation with 50 μg/ml of ICRF-187 (+) or DMSO (−) for days 0–2 or 3–5, probed with
anti-PPARγ, anti-PARP and β-actin as a loading control, H. PPARγ1 and 2 from day 5 (D5) of Western blots were then quantiﬁed, relative band density was normalised to β-actin and
then to DMSO (−). All quantiﬁcations are calculated from a minimum of 3 independent experiments, shown as means ± SDs.
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entiation and concomitantly with DNA synthesis [48]. Tang and Lane
[48] suggest that the association of C/EBPβ and δwith centromeric het-
erochromatin is functionally important for the regulation of MCE as this
may delay their acquisition of DNA binding activity and hence the tran-
scription of C/EBPα and PPARγ. Considering that C/EBPα is a mitoticrepressor, the delayed expression of C/EBPα is hence thought to ensure
the completion of MCE [49]. In addition, C/EBPβ has been shown to in-
duce the transient expression of the methyl transferase G9a during
MCE, which leads to histone H3K9 dimethylation on the promoters of
C/EBPα and PPARγ and their repression [50]. In our study, we show
that Topo II inhibition with the addition of ICRF-187 caused a higher
Fig. 5. Topo IIα activity during mitotic clonal expansion phase of adipogenesis. A. EdU labelling and Topo IIα immunostaining of 3T3-L1 cells on days 0 (D0), 1 (D1) and 2 (D2) of
differentiation in the presence of 50 μg/ml of ICRF-187 (+) or DMSO (−), nuclear counterstained with Hoechst, Side panels are magniﬁed examples of Topo IIα and EdU staining from
day 1 with DMSO control, scale bar indicates 10 μm (40×). B. Quantiﬁcation of 3T3-L1 cells positive for Topo IIα and EdU (Topo IIα+ EdU+, orange), Topo IIα only (Topo IIα+
EdU−, green), EdU only (Topo IIα− EdU+, red) or neither Topo IIα nor EdU (Topo IIα− EdU−, blue) on day 0 (D0), 1 (D1) and 2 (D2) in the presence of 50 μg/ml of ICRF-187 (+)
or DMSO (−). At least 300 3T3-L1 cells were counted from a minimum of 5 different 40× ﬁelds per experiment. C. Quantiﬁcation of staining patterns of Topo IIα, categorised as either
pericentromeric heterochromatin (PCH) or diffuse. The percentages are calculated from total number of Topo IIα positive cells for each condition per experiment. D. Quantiﬁcation of
relative nuclei numbers on day 1 (D1) and 2 (D2) of 3T3-L1 cells treated with 50 μg/ml of ICRF-187 (+) or DMSO (−). Nuclei were counted from a minimum of 5 different 40× ﬁelds
per experiment and the average number of Hoechst-stained nuclei per ﬁeld was normalised to day 0 (D0). All quantiﬁcations calculated from 3 independent experiments, graphs
shown as mean ± SD.
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action of the inhibitor. ICRF-187 is a member of the bisdioxopiperazines
class of Topo II catalytic inhibitors, which are known to trap Topo II on
DNA as a protein-DNA clamp [43–45]. DNA-trapped Topo IIα mayindicate the sites of Topo IIα activity, which are particularly noticeable
in heterochromatin, consistent with a study in human cells by
Agostinho et al. [47]. Topo IIαmay therefore have a role in the replica-
tion of heterochromatin. However our study did not uncover a role for
1601R.G. Jacobsen et al. / Cellular Signalling 28 (2016) 1593–1603Topo II in DNA synthesis since its inhibitionwith ICRF-187 led to a small
increase in EdU labelling at day 1 rather than a decrease, whichwasmir-
rored by a slight increase in cyclin A (data not shown). These results
may instead be indicative of a delay in the progression of DNA replica-
tion. Consistently, Topo IIα inhibition with another bisdioxopiperazine
Topo II catalytic inhibitor, ICRF-193, in Xenopus sperm nuclei did not
alter entry into S phase and DNA synthesis but delayed the completion
of DNA replication [51] due to the perturbation of chromatin structure
[52]. The localisation of Topo IIα to chromocenters or centromeric chro-
matin has previously been reported [47,53] and shown to play a role
correlated to the accurate segregation of chromatids in anaphase [54].
In line with this, Topo inhibition with ICRF-187 has been shown to
cause the incomplete segregation of chromosomes [55]. These reports
would hence support a role for Topo IIα at the centromeres during mi-
tosis of 3T3-L1 pre-adipocytes. Consistently, we showed that ICRF-187
induced a decrease in the average number of cells at day 2. In addition,
DNA-trapped Topo IIαmay be stable and may prevent its degradation,
as shown in other studies using ICRF-193 [56,57], and thismight explain
why the number of Topo IIα positive cells remains high in day 2 with
ICRF-187 compared to the overall decreased protein levels detected by
immunoblotting at day 2 without the inhibitor.
Previous studies in 3T3-L1 cells showed that Topo II activity is neces-
sary for PARP1 (alias ARTD1) activation and the recruitment of PARP1 to
PPARγ response elements (PPREs) of PPARγ-dependent adipogenic
genes and therefore for their subsequent expression and adipocyte dif-
ferentiation [41,42]. However, these studies showed a later contribution
for Topo II-dependent PARP1 activity and PARP1 recruitment to PPREs
which were demonstrated at day 7 (equivalent to day 5 in our study)
in cells treated with an inhibitor of Topo II at days 4/5–6 (equivalent
to days 2/3–4 in our study). In light of our results, inhibition of Topo II
at these time points would more likely target Topo IIβ rather than
Topo IIα, since its expression is still detectable, and points therefore to
a role for Topo IIβ in the regulation of PARP1 mediated adipogenic
gene expression at these time points. Topo IIβ and PARP1 have indeed
been shown to be part of the same protein complex and to be important
in activating transcription via the local formation of dsDNA breaks in a
number of other studies [58–60]. Consistently, a role for Topo IIβ in
transcription linked to cell differentiation is supported in another
study showing the recruitment of Topo IIβ along with PARP1 on the
fatty acid synthase (FAS) promoter in hepatocytes responding to insulin
during lipogenesis [61]. Therefore, Topo IIβmay also contribute since it
is expressed continually throughout differentiation. Both isoforms may
hence operate catalytically similarly but on different genomic sites
and times of differentiation since they appear to be targeted to different
nuclear sites, as detected by immunostaining.
It is well known that the addition of pan PI3K inhibitors such as
LY294002 or wortmannin inhibits adipogenesis in 3T3-L1 cells [21,23,
25,39,62]. Rapamycin, an inhibitor of mTOR, has also been shown to in-
hibit the differentiation of 3T3-L1 cells by inhibitingMCE [39,40] and Rb
protein phosphorylation [39]. Our studies conﬁrmed the effect of PI3K
and mTOR inhibition on adipogenesis using LY294002 and rapamycin.
We also showed that this was accompanied by reduced expression of
Topo IIα, indicating that the PI3K/mTOR pathway regulates the expres-
sion of Topo IIα duringMCE in these cells. The expression of Topo IIβ ex-
hibited a lot of variations but did not seem to be regulated by the PI3K
pathway.
Since LY294002 is a pan-PI3K inhibitor we wondered if the effect
seen on differentiation and expression of Topo IIα could be attributed
to a particular PI3K class IA catalytic subunit isoform. We ﬁnd that
3T3-L1 cells express all class IA PI3K catalytic isoforms, i.e. p110α, β
and δ, and that their expression levels remain relatively constant during
the differentiation time course. Previous reports showed some slight
variations in the levels of these isoforms in 3T3-L1 cells during differen-
tiation, i.e. showing an increase in p110β [63], or an increase in p110α
levels and a decrease in p110δ [23]. These slight differences may be lon-
ger differentiation protocol for up to 9 days [23]. Using selectiveinhibitors, our study shows that p110α and p110δ, to a lesser extent,
are required for adipocyte differentiation. The major contribution of
p110α in adipogenesis is in agreementwith the study of Kim, Shepherd
and Chaussade [23] using a different selective inhibitor.Moreover, other
studies have shown p110α to be the main isoform involved in mediat-
ing insulin signalling in 3T3-L1 cells [64,65]. These results correlated
well with the effects seen on Topo IIα expression, which was strongly
regulated by p110α. We also observed a reduction in the expression
of Topo IIα following the inhibition of p110β and p110δ but high con-
centrations of the inhibitors were required, i.e. 10 μM. Therefore,
p110α seems to be the major regulator of adipogenesis and expression
of Topo IIα, while p110β and δmay have some more minor contribu-
tions since high concentrations of the inhibitors may not be reliable
and lead to unspeciﬁc effects. However, the p110β inhibitor, TGX-221,
has been reported to be selective and without off-target effects when
used at 10 μM, although it is reported to cross-react with p110δ [66].
5. Conclusions
In summary, we have shown that Topo IIα expression peaks at the
early stages of 3T3-L1 differentiation into adipocytes in a PI3K/mTOR-
dependentmanner and that it is essential for adipogenesis. All isoforms
of the catalytic class IA PI3K seem to contribute, although p110α is the
most dominant. The timing of Topo IIα expression coincides with the
MCE phase where Topo IIα seems to have a role maybe in the replica-
tion of the heterochromatin regions, and perhaps in chromatin struc-
ture. Inhibiting Topo II after MCE and therefore when the expression
of Topo IIα has declined has less effect on differentiation and expression
of PPARγ, hence pointing to an important role in the early stages of dif-
ferentiation for terminal differentiation. The results of this study may
have implications in cancer considering that Topo II enzymes are targets
of chemotherapy agents [67]. Thus, inhibition of Topo II in the course of
cancer chemotherapy may have deleterious effects on the integrity of
the adipose tissuewhichmay have implications in the treatment of can-
cer in diabetic patients. Indeed, the chemotherapeutic Doxorubicin,
which inhibits Topo II, has side effects with great loss of adipose tissue
andmusclemass, was shown in a recent study to induce hyperglycemia
and insulin resistance in rat [68].
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